0001209191-16-149229.txt : 20161110
0001209191-16-149229.hdr.sgml : 20161110
20161110082602
ACCESSION NUMBER: 0001209191-16-149229
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20161109
FILED AS OF DATE: 20161110
DATE AS OF CHANGE: 20161110
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930797222
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-274-4000
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mahatme Sandesh
CENTRAL INDEX KEY: 0001511034
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 161986099
MAIL ADDRESS:
STREET 1: C/O CELGENE CORPORATION
STREET 2: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-11-09
0
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001511034
Mahatme Sandesh
215 FIRST STREET, SUITE 415
CAMBRIDGE
MA
02142
0
1
0
0
Senior Vice President, CFO
Common Stock
2016-11-09
4
M
0
1000
23.85
A
32532
D
Incentive Stock Option (right to buy)
23.85
2016-11-09
4
M
0
1000
0.00
D
2022-11-05
Common Stock
1000
15768
D
Includes 15,300 Restricted Stock Award ("RSA") that will vest upon the Company exceeding $80 million in total revenue reported in publicly released GAAP financials, in any fiscal quarter between grant date and June 30, 2018, and an additional 3,825 RSAs that will vest during the same period if the total revenue reported in the publicly released GAAP financials exceeds $100 million.
25% of the option became exercisable on the first anniversary of the date of hire (11/05/2012) and 1/48th of the total granted option became exercisable on each monthly anniversary thereafter, such that the option became fully exercisable on the fourth anniversary of the date of hire.
/s/David Tyronne Howton, as Attorney-in-Fact for Sandesh Mahatme
2016-11-10